[1] |
刘茜羽, 张孟, 于庆功. 慢性胃病临床特点及胃蛋白酶原联合胃泌素17临床诊断价值分析[J]. 世界最新医学信息文摘(连续型电子期刊), 2019, 19(71):54-56.
|
|
Liu QY, Zhang M, Yu QG. Clinical Characteristics of Chronic Gastric Diseases and Clinical Diagnostic Value of Pepsinogen Combined with Gastrin 17[J]. World Latest Med Inform, 2019, 19(71):54-56.
|
[2] |
高雪艳, 冯义朝. 血清胃蛋白酶原水平在胃部疾病中的临床应用及意义[J]. 世界最新医学信息文摘(连续型电子期刊), 2016, 16(50):53-54.
|
|
Gao XY, Feng YC. Clinical application and significance of serum pepsinogen level in gastric diseases[J]. World Latest Med Inform, 2016, 16(50):53-54.
|
[3] |
周勃. 血清胃蛋白酶原在临床胃部疾病中的研究进展[J]. 继续医学教育, 2021, 35(11):128-130.
|
|
Zhou B. Research progress of serum pepsinogen in clinical gastric diseases[J]. Contin Med Educ, 2021, 35(11):128-130.
|
[4] |
Mansour-Ghanaei F, Joukar F, et al. Only serum pepsinogen I and pepsinogen Ⅰ/Ⅱ ratio are specific and sensitive biomarkers for screening of gastric cancer[J]. Biomol Concepts, 2019, 10(1):82-90.
doi: 10.1515/bmc-2019-0010
pmid: 31188744
|
[5] |
甘建, 程荣贵, 王韶峰. 血清胃蛋白酶原对胃部疾病的诊断价值[J]. 世界华人消化杂志, 2018, 26(36):2115-2119.
|
|
Gan J, Chen RG, Wang SF. Diagnostic value of serum pepsinogen in gastric diseases[J]. World Chin J Digestology, 2018, 26(36):2115-2119.
doi: 10.11569/wcjd.v26.i36.2115
URL
|
[6] |
刘兰凤, 杜丽新, 刘海燕, 等. 血清胃蛋白酶原检测在诊断胃部疾病中的应用价值[J]. 当代医药论丛, 2018, 16(21):167-168.
|
|
Liu LF, Du LX, Liu HY, et al. Application value of serum pepsinogen detection in the diagnosis of gastric diseases[J]. Contemp Med Forum, 2018, 16(21):167-168.
|
[7] |
Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels - "ABC method"[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2011, 87(7):405-414.
doi: 10.2183/pjab.87.405
URL
|
[8] |
Yamaguchi Y, Nagata Y, Hiratsuka R, et al. Gastric Cancer Screening by Combined Assay for Serum Anti-Helicobacter pylori IgG Antibody and Serum Pepsinogen Levels--The ABC Method[J]. Digestion, 2016, 93(1):13-18.
doi: 10.1159/000441742
pmid: 26789514
|
[9] |
Watson SA, Grabowska AM, El-Zaatari M, et al. Gastrin - active participant or bystander in gastric carcinogenesis?[J]. Nat Rev Cancer, 2006, 6(12):936-946.
pmid: 17128210
|
[10] |
Kikuchi R, Abe Y, Iijima K, et al. Low serum levels of pepsinogen and gastrin 17 are predictive of extensive gastric atrophy with high-risk of early gastric cancer[J]. Tohoku J Exp Med, 2011, 223(1):35-44.
pmid: 21222340
|
[11] |
Zagari RM, Rabitti S, Greenwood DC, et al. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis[J]. Aliment Pharmacol Ther, 2017, 46(7):657-667.
doi: 10.1111/apt.14248
URL
|
[12] |
Tu H, Sun L, Dong X, et al. A Serological biopsy using five stomach-specific circulating biomarkers for gastric cancer risk assessment: a multi-phase study[J]. Am J Gastroenterol, 2017, 112(5):704-715.
doi: 10.1038/ajg.2017.55
pmid: 28323271
|
[13] |
Correa P. Human gastric carcinogenesis: a multistep and multifactorial process--First American Cancer Society award lecture on cancer epidemiology and prevention[J]. Cancer Res, 1992, 52(24):6735-6740.
pmid: 1458460
|
[14] |
Wang Y, Zhu Z, Liu Z, et al. Diagnostic value of serum pepsinogen I, pepsinogen Ⅱ, and gastrin-17 levels for population-based screening for early-stage gastric cancer[J]. J Int Med Res, 2020, 48(3):300060520914826.
|
[15] |
雷雅莉, 苌新明. 血清胃泌素-17与胃蛋白酶原诊断胃癌价值研究[J]. 人民军医, 2020, 63(5):474-476,487.
|
|
Lei YL, Chang XM. Diagnostic value of serum gastrin-17 and pepsinogen in gastric cancer[J]. People′s Mil Surg, 2020, 63(5):474-476,487.
|
[16] |
朱正其, 赵缜, 曹国君, 等. 早期胃癌患者血清PGⅠ/PGⅡ、G-17及抗-Hp的检测及临床价值探讨[J]. 国际检验医学杂志, 2020, 41(8):996-998.
|
|
Zhu ZQ, Zhao Z, Cao GJ, et al. Detection and clinical value of serum PG Ⅰ /pg Ⅱ, G-17 and anti HP in patients with early gastric cancer[J]. Int J Lab Med, 2020, 41(8):996-998.
|
[17] |
Wang Y, Zhu Z, Liu Z, et al. Diagnostic value of serum pepsinogen I, pepsinogen II, and gastrin-17 levels for population-based screening for early-stage gastric cancer[J]. J Int Med Res, 2020, 48(3):300060520914826.
|
[18] |
Cao XY, Jia ZF, Jin MS, et al. Serum pepsinogen Ⅱ is a better diagnostic marker in gastric cancer[J]. World J Gastroenterol, 2012, 18(48):7357-7361.
doi: 10.3748/wjg.v18.i48.7357
URL
|
[19] |
Sugano K. Effect of Helicobacter pylori eradication on the incidence of gastric cancer: a systematic review and meta-analysis[J]. Gastric Cancer, 2019, 22(3):435-445.
doi: 10.1007/s10120-018-0876-0
pmid: 30206731
|
[20] |
Lee YC, Chiang TH, Chou CK, et al. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis[J]. Gastroenterology, 2016, 150(5):1113-1124,e5.
doi: 10.1053/j.gastro.2016.01.028
URL
|
[21] |
袁玉涛. 胃癌早期诊断中血清胃蛋白酶原及幽门螺杆菌抗体的价值分析[J]. 当代医学, 2019, 25(31):107-109.
|
|
Yuan YT. Value of serum pepsinogen and Helicobacter pylori antibodies in early diagnosis of gastric cancer[J]. Contemp Med, 2019, 25(31):107-109.
|